[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-460649-105":59,"doc-detail-460649-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","understanding-the-burden-of-anca-associated-vasculitis","Understanding the burden of ANCA-associated vasculitis","","Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a relapsing systemic autoimmune disease causing vasculitis-related organ damage and chronic-inflammation comorbidities. Immunosuppression advances have improved remission, lowered relapse risk, and increased survival, yet overall mortality remains high versus the general population. Treatment benefits are often reduced by adverse effects—especially infections—plus treatment-related comorbidities and organ damage. This review examines major contributors to disease burden and outlines strategies to improve health-related quality of life.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/understanding-the-burden-of-anca-associated-vasculitis/460649/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/understanding-the-burden-of-anca-associated-vasculitis/460649.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What does AAV disease burden include?","Question",{"text":113,"@type":114},"AAV disease burden includes organ impairment, inflammation-related comorbidities, treatment-related adverse effects, relapse, and reduced survival.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do immunosuppression advances change outcomes in AAV?",{"text":118,"@type":114},"Advances in immunosuppression-based therapies improve remission rates, reduce relapse risk, and improve survival. However, mortality remains higher than in the general population.",{"name":120,"@type":111,"acceptedAnswer":121},"Why is glucocorticoid exposure important in AAV management?",{"text":122,"@type":114},"Reducing glucocorticoid exposure can improve health-related quality of life and reduce treatment-related adverse effects.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},460649,1790929883,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Original Article  \nUnderstanding the burden of ANCA-associated vasculitis  \nBernhard Hellmich 1, 􀀃  \n1 Klinik f€ur Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius KLINIKEN Kirchheim-Teck & N€urtingen, Akademisches Lehrkrankenhaus der Universit€at T€ubingen, Kirchheim unter Teck, Germany  \n􀀃 Correspondence to: Bernhard Hellmich, Klinik f€ur Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius KLINIKEN Kirchheim-Teck & N€urtingen, Akademisches Lehrkrankenhaus der Universit€at T€ubingen, Eugenstraße 3, 73230 Kirchheim unter Teck, Germany. E-mail: b.hellmich@medius-kl[iniken.de](iniken.de)  \nAbstract  \nAnti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of frequently relapsing systemic autoimmune disorders characterized by vasculitis-related organ damage and multiple comorbidities related to chronic inflammation. Advances in immunosuppressionbased therapies for AAV have considerably improved remission rates, reduced the risk of relapse, and improved survival in patients with AAV. However, mortality remains high compared with the general population and the benefits of treatment are often offset by treatment-related comorbidities, organ damage and adverse effects, particularly infections. The aim of this review is to investigate the key contributors to disease burden in patients with AAV and to describe strategies for improving health-related quality of life.  \nGraphical abstract  \nKeywords: Anti-neutrophil cytoplasmic antibody, ANCA-associated vasculitis, AAV, disease burden, health-related quality of life, immunosuppression, glucocorticoids, avacopan  \nRheumatology key messages  \n􀀏 AAV disease burden includes organ impairment, inflammation-related comorbidities, treatment-related adverse effects, relapse, and reduced survival.  \n􀀏 Rituximab reduces the risk of AAV relapse, organ damage and comorbidities in AAV patients.  \n􀀏 Reducing glucocorticoid exposure improves quality of life and reduces treatment-related adverse effects.  \nReceived: 6 August 2025. Accepted: 22 August 2025  \n© The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.  \nBurden of ANCA-associated vasculitis i7  \nIntroduction  \nAnti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune vascular disorders which includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA) [1, 2]. Early AAV is characterized by the signs and symptoms of chronic inflammatory diseases, such as fatigue, weight loss, myalgia, and polyarthralgia. As the disease progresses, patients are at risk of developing vasculitisrelated organ impairment and comorbidities associated with chronic inflammation, including diabetes mellitus, hypertension, and cardiovascular diseases (CVD). The aims of treatment are to reduce the risk of organ damage by rapidly controlling active disease and preventing AAV relapse [3, 4]. This is achieved using immunosuppression-based therapies [typically rituximab (RTX) or cyclophosphamide (CYC) alongside glucocorticoids (GC)] and avacopan [3–5]. Although effective, immunosuppression is associated with a high risk of adverse events (AE) (particularly infections) and drug-related organ damage/comorbidities. The overall consequences of AAV and AAV treatments include limited survival, organ impairment, chronic pain and multiple other symptoms, many of which contribute to a reduced healthrelated quality of life (HRQoL). The aim of this review is to investigate the key factors contributing to disease bu","cbCaiaDPjWL2coUz","https://ap.wps.com/l/cbCaiaDPjWL2coUz","pdf",920130,"English","# Abstract\n# Rheumatology key messages\n# Introduction\n# AAV disease burden\n## Mortality\n## AAV relapse","[{\"question\":\"What does AAV disease burden include?\",\"answer\":\"AAV disease burden includes organ impairment, inflammation-related comorbidities, treatment-related adverse effects, relapse, and reduced survival.\"},{\"question\":\"How do immunosuppression advances change outcomes in AAV?\",\"answer\":\"Advances in immunosuppression-based therapies improve remission rates, reduce relapse risk, and improve survival. However, mortality remains higher than in the general population.\"},{\"question\":\"Why is glucocorticoid exposure important in AAV management?\",\"answer\":\"Reducing glucocorticoid exposure can improve health-related quality of life and reduce treatment-related adverse effects.\"}]","Understanding the burden of ANCA-associated vasculitis | PDF",1790758969,15]